This SuperSeries is composed of the SubSeries listed below.
Overall design: Refer to individual Series
| Accession | PRJNA472052; GEO: GSE114649 |
| Type | Umbrella project |
| Publications | - Yan B et al., "Low-frequency TP53 hotspot mutation contributes to chemoresistance through clonal expansion in acute myeloid leukemia.", Leukemia, 2020 Jul;34(7):1816-1827
- Yan B et al., "Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia.", Leukemia, 2019 Apr;33(4):931-944
|
| Submission | Registration date: 18-May-2018
University of Florida |
| Relevance | Superseries |
Project Data:
| Resource Name | Number
of Links |
|---|
| Sequence data |
| SRA Experiments | 6 |
| Publications |
| PubMed | 2 |
| PMC | 1 |
| Other datasets |
| BioSample | 6 |
| GEO DataSets | 3 |
Epigenetic drugs selectively target a population of AML cells which are positive for CD123 cell surface markers and are chemoresistant encompasses the following 2 sub-projects:
| Project Type | Number of Projects |
| Transcriptome or Gene expression | 2 |
BioProject
accession | Organism | Title |
|---|
| PRJNA472053 | Homo sapiens | Epigenetic drugs selectively target a population of AML cells which are positive for CD123 cell surface markers and are chemoresistant II (University of Florida) | | PRJNA422583 | Homo sapiens | Epigenetic drugs selectively target a population of AML cells which are positive for CD123 cell surface markers and are chemoresistant I (University of Florida) |
|